{"disease":{"id":"atezolizumab-and-bevacizumab-in-hepatocellular-carcinoma","name":"atezolizumab and bevacizumab in hepatocellular carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07495735","title":"Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06416683","title":"Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)","phase":"","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"University Hospital, Caen","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}